RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SAGE Therapeutics Stock

SAGE Therapeutics Net Income 2024

SAGE Therapeutics Net Income

-406.8 M USD

Ticker

SAGE

ISIN

US78667J1088

WKN

A117WF

In 2024, SAGE Therapeutics's profit amounted to -406.8 M USD, a -24.87% increase from the -541.49 M USD profit recorded in the previous year.

The SAGE Therapeutics Net Income history

YEARNET INCOME (undefined USD)
2029e694.32
2028e101.68
2027e-18.5
2026e-229.79
2025e-315.89
2024e-406.8
2023-541.49
2022-532.8
2021-457.9
2020606.1
2019-680.2
2018-372.9
2017-270.1
2016-159
2015-94.5
2014-36.1
2013-18.3
2012-9.6

SAGE Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SAGE Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SAGE Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SAGE Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SAGE Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SAGE Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SAGE Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SAGE Therapeutics’s growth potential.

SAGE Therapeutics Revenue, EBIT and net profit per share

DateSAGE Therapeutics RevenueSAGE Therapeutics EBITSAGE Therapeutics Net Income
2029e892.58 M undefined0 undefined694.32 M undefined
2028e618.34 M undefined117.41 M undefined101.68 M undefined
2027e404.8 M undefined-79.58 M undefined-18.5 M undefined
2026e187.04 M undefined-236.45 M undefined-229.79 M undefined
2025e96.78 M undefined-321.97 M undefined-315.89 M undefined
2024e39.62 M undefined-432.73 M undefined-406.8 M undefined
202386.46 M undefined-546.46 M undefined-541.49 M undefined
20227.7 M undefined-547 M undefined-532.8 M undefined
20216.3 M undefined-460.9 M undefined-457.9 M undefined
20201.11 B undefined623.9 M undefined606.1 M undefined
20196.9 M undefined-708.1 M undefined-680.2 M undefined
201890.3 M undefined-393.2 M undefined-372.9 M undefined
20170 undefined-273.2 M undefined-270.1 M undefined
20160 undefined-160.2 M undefined-159 M undefined
20150 undefined-94.7 M undefined-94.5 M undefined
20140 undefined-33.8 M undefined-36.1 M undefined
20130 undefined-18.3 M undefined-18.3 M undefined
20120 undefined-9.6 M undefined-9.6 M undefined

SAGE Therapeutics stock margins

The SAGE Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SAGE Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SAGE Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SAGE Therapeutics's sales revenue. A higher gross margin percentage indicates that the SAGE Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SAGE Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SAGE Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SAGE Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SAGE Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SAGE Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SAGE Therapeutics Margin History

SAGE Therapeutics Gross marginSAGE Therapeutics Profit marginSAGE Therapeutics EBIT marginSAGE Therapeutics Profit margin
2029e97.5 %0 %77.79 %
2028e97.5 %18.99 %16.44 %
2027e97.5 %-19.66 %-4.57 %
2026e97.5 %-126.42 %-122.86 %
2025e97.5 %-332.68 %-326.39 %
2024e97.5 %-1,092.17 %-1,026.72 %
202397.5 %-632.08 %-626.32 %
202289.61 %-7,103.9 %-6,919.48 %
202192.06 %-7,315.87 %-7,268.25 %
202099.95 %56 %54.4 %
201994.2 %-10,262.32 %-9,857.97 %
201897.5 %-435.44 %-412.96 %
201797.5 %0 %0 %
201697.5 %0 %0 %
201597.5 %0 %0 %
201497.5 %0 %0 %
201397.5 %0 %0 %
201297.5 %0 %0 %

SAGE Therapeutics Aktienanalyse

What does SAGE Therapeutics do?

SAGE Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding SAGE Therapeutics's Profit Margins

The profit margins of SAGE Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of SAGE Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating SAGE Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

SAGE Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When SAGE Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about SAGE Therapeutics stock

How much profit has SAGE Therapeutics made this year?

SAGE Therapeutics has made -406.8 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -24.87% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does SAGE Therapeutics publish its earnings?

SAGE Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of SAGE Therapeutics?

The profits of SAGE Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of SAGE Therapeutics?

You can learn more about the earnings of SAGE Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does SAGE Therapeutics pay?

Over the past 12 months, SAGE Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SAGE Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of SAGE Therapeutics?

The current dividend yield of SAGE Therapeutics is .

When does SAGE Therapeutics pay dividends?

SAGE Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SAGE Therapeutics?

SAGE Therapeutics paid dividends every year for the past 0 years.

What is the dividend of SAGE Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is SAGE Therapeutics located?

SAGE Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von SAGE Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SAGE Therapeutics from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did SAGE Therapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of SAGE Therapeutics in the year 2023?

In the year 2023, SAGE Therapeutics distributed 0 USD as dividends.

In which currency does SAGE Therapeutics pay out the dividend?

The dividends of SAGE Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SAGE Therapeutics

Our stock analysis for SAGE Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SAGE Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.